SAGE News and Press, Sage Therapeutics Inc. From 03/27/23

2023-03-27 09:01:14 ET FinancialBuzz.com News Commentary New York, NY (3/27/2023) – Potash is an essential nutrient for plants, particularly in the growth and development of their roots. It is a naturally occurring mineral that contains potassium in water-soluble form, an...

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Stifel 2023 CNS Days on Wednesday, March 29, 2023, at 11:00 a.m. ET. A live webcast of the presentation can be a...

2023-03-21 09:00:10 ET FinancialBuzz.com News Commentary New York, NY (3/21/2023) – Potash includes various mined and manufactured salts that contain potassium in water-soluble form. Potassium, as one of the three main macronutrients, is in high demand as a fertilizer. As...

2023-03-20 16:51:33 ET FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “SAGE POTASH CORP. IDENTIFIES LARGE-SCALE, HIGH-GRADE, US-BASED POTASH RESOURCE AND COMMENCES TRADING ON THE TSX-V UNDER THE SYMBOL “SAGE”.&...

2023-03-20 10:52:33 ET FinancialBuzz.com’s latest Behind the Buzz Show: Featuring Our Potash Corp. Corporate Overview Sage Potash Corp. (TSX-V: SAGE) is a Canadian company that intends to become a prominent domestic potash producer within the Paradox Basin situ...

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the appointment of Jessica Federer to the company’s Board of Directors. This press release features multimedia. View the full release here: ...

2023-03-13 10:58:31 ET RBC Capital Markets upgraded Sage Therapeutics ( NASDAQ: SAGE ) to outperform from underperform as it sees a stronger likelihood that depression candidate zuranolone will win approval from the US FDA. The firm also upped its price target to $60 from ...

Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) notified the companies that the agency does not currently plan to convene an advisory committee meeting to discuss the New Drug Application (NDA) for zuranolone in ...

2023-03-07 02:47:50 ET Summary Biogen Q4 revenue was down 7% y/y. Zuranolone is a breakthrough depression therapy with an August 5, 2023, PDUFA date. Leqembi could generate strong revenue with full approval, but reimbursement remains an issue. Biogen ( BIIB ) has...

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Cowen 43 rd Annual Health Care Conference on Monday, March 6, 2023, at 10:30 a.m. ET in Boston, MA. A live w...